Relmada Therapeutics
RLMD
43 hedge funds and large institutions have $319M invested in Relmada Therapeutics in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 9 closing their positions.
29,233% more call options, than puts
Call options by funds: $880K | Put options by funds: $3K
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
20% more capital invested
Capital invested by funds: $265M → $319M (+$54.1M)
14.83% more ownership
Funds ownership: 47.8% → 62.63% (+15%)
4% less funds holding
Funds holding: 45 → 43 (-2)
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$46.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.9M |
| 3 |
BlackRock
New York
|
+$13.5M |
| 4 |
RI
RTW Investments
New York
|
+$12.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.67M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.05M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$390K |
| 4 |
Squarepoint
New York
|
-$348K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
-$273K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
51
Prelude Capital Management
New York
| – | -$5K | -121 | Closed |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -36 | Closed |
|
RLMD Hedge Fund Activity: Q1 2020 in Review
43 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2020, worth a combined $319M — up 20% from $265M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RLMD positions and 9 closed out — a net gain of 2 holders — while 18 added to existing stakes and 7 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $46.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $5.34M sold.
- 43 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2020, down from 45 in Q4 2019.
- Funds reported $319M of Relmada Therapeutics stock for Q1 2020, up 20% quarter-over-quarter.
- 11 funds opened new Relmada Therapeutics positions in Q1 2020 and 9 closed out, a net change of +2 holders.
- The largest Relmada Therapeutics buyer in Q1 2020 was Avoro Capital Advisors, an estimated $46.4M added.
- The largest Relmada Therapeutics seller in Q1 2020 was Point72 Asset Management, an estimated $5.34M sold.
Based on aggregated 13F filings for Q1 2020.